NCT06850792Recruiting
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce
imprOving Adherence to Pulmonary artErial hyperteNsion Treatment With teLemedicIne and patieNt guidaNce - A Multicenter Pre- and Post-intervention Evaluation Study
Source: ClinicalTrials.gov · Last updated 10 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 61 (estimated)
- First submitted
- 22 Feb 2025
- Start date
- 7 May 2025
- Primary completion date
- Apr 2028
- Lead sponsor
- University of Sao Paulo General Hospital
- NCT number
- NCT06850792
What you commit to
- Study type: Interventional
- Planned participants: 61
- From 7 May 2025 to the primary completion date, Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in another interventional clinical trial that could interfere with outcomes.
Other illness
- Severe cognitive impairment or psychiatric disorders that could affect adherence or study participation.
- Life expectancy \<6 months due to any condition unrelated to PAH.
Other
- Inability to communicate via phone or telemedicine due to technical or personal constraints.
- Pregnancy or breastfeeding.
Who the study is looking for
- Adults aged ≥18 years diagnosed with pulmonary arterial hypertension (PAH) (Group 1 of the WHO classification).
- Stable oral PAH therapy (including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin pathway agents) for at least four weeks prior to enrollment.
- Ability to participate in remote teleconsultations (access to a phone or internet).
- Signed informed consent agreeing to study participation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| InCor - Universidade de São Paulo Coordinator of this site? Confirm its status | São Paulo | Brazil | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.